{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:31:31Z","timestamp":1775079091110,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,15]]},"DOI":"10.1097\/qai.0b013e31820a4a8d","type":"journal-article","created":{"date-parts":[[2011,1,15]],"date-time":"2011-01-15T06:10:49Z","timestamp":1295071849000},"page":"384-392","source":"Crossref","is-referenced-by-count":9,"title":["Combinations of 3-Hydroxyphthalic Anhydride-Modified Ovalbumin With Antiretroviral Drug-Based Microbicide Candidates Display Synergistic and Complementary Effects Against HIV-1 Infection"],"prefix":"10.1097","volume":"56","author":[{"given":"Lin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suiyi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210131","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1095\/biolreprod.102.014555","article-title":"Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development.","volume":"69","author":"Perotti","year":"2003","journal-title":"Biol Reprod"},{"key":"R2-2-20210131","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/QAI.0b013e31815d2f12","article-title":"No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial.","volume":"47","author":"Bollen","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-2-20210131","first-page":"12","article-title":"Scientists rethink approach to HIV gels.","volume":"446","author":"Check","year":"2007","journal-title":"Nature"},{"key":"R4-2-20210131","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMoa0707957","article-title":"Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.","volume":"359","author":"Van","year":"2008","journal-title":"N Engl J Med"},{"key":"R5-2-20210131","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1097\/OLQ.0b013e318199417d","article-title":"Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides.","volume":"36","author":"Keller","year":"2009","journal-title":"Sex Transm Dis"},{"key":"R6-2-20210131","doi-asserted-by":"crossref","first-page":"b5538","DOI":"10.1136\/bmj.b5538","article-title":"Microbicide offers no protection against HIV infection.","volume":"339","author":"Roehr","year":"2009","journal-title":"BMJ"},{"key":"R7-2-20210131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/QCO.0b013e328334fe70","article-title":"Microbicides for HIV prevention: reality or hope?","volume":"23","author":"McGowan","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"R8-2-20210131","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nm0502-425","article-title":"AIDS models: microbicides could learn from vaccines.","volume":"8","author":"Shattock","year":"2002","journal-title":"Nat Med"},{"key":"R9-2-20210131","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1128\/AAC.48.10.3834-3844.2004","article-title":"In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.","volume":"48","author":"Dezzutti","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-2-20210131","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(08)70254-8","article-title":"Vaginal microbicides and the prevention of HIV transmission.","volume":"8","author":"Cutler","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R11-2-20210131","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/OLQ.0b013e318162c4d8","article-title":"A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.","volume":"35","author":"Schwartz","year":"2008","journal-title":"Sex Transm Dis"},{"key":"R12-2-20210131","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.virol.2007.03.001","article-title":"Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.","volume":"364","author":"Ketas","year":"2007","journal-title":"Virology"},{"key":"R13-2-20210131","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1080\/09540120701294237","article-title":"Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).","volume":"19","author":"Carballo-Dieguez","year":"2007","journal-title":"AIDS Care"},{"key":"R14-2-20210131","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.aids.0000210608.70762.c3","article-title":"Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.","volume":"20","author":"Mayer","year":"2006","journal-title":"AIDS"},{"key":"R15-2-20210131","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/jwh.2006.0325","article-title":"Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.","volume":"17","author":"Rosen","year":"2008","journal-title":"J Womens Health (Larchmt)"},{"key":"R17-2-20210131","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.","volume":"329","author":"Karim","year":"2010","journal-title":"Science"},{"key":"R18-2-20210131","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1128\/AAC.01046-09","article-title":"3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1.","volume":"54","author":"Li","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-2-20210131","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0378-4347(01)00108-6","article-title":"Structure and properties of ovalbumin.","volume":"756","author":"Huntington","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R20-2-20210131","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1432-1033.1981.tb05243.x","article-title":"The complete amino-acid sequence of hen ovalbumin.","volume":"115","author":"Nisbet","year":"1981","journal-title":"Eur J Biochem"},{"key":"R21-2-20210131","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1021\/bi7001289","article-title":"Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.","volume":"46","author":"Deng","year":"2007","journal-title":"Biochemistry"},{"key":"R22-2-20210131","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","article-title":"A vaginal fluid simulant.","volume":"59","author":"Owen","year":"1999","journal-title":"Contraception"},{"key":"R23-2-20210131","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jmr.300080504","article-title":"Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis.","volume":"8","author":"Neurath","year":"1995","journal-title":"J Mol Recognit"},{"key":"R24-2-20210131","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nm0296-230","article-title":"Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV.","volume":"2","author":"Neurath","year":"1996","journal-title":"Nat Med"},{"key":"R25-2-20210131","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1084\/jem.174.6.1557","article-title":"Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120\/gp41.","volume":"174","author":"Jiang","year":"1991","journal-title":"J Exp Med"},{"key":"R26-2-20210131","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1128\/AAC.48.11.4349-4359.2004","article-title":"N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.","volume":"48","author":"Jiang","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-2-20210131","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/aid.2006.22.411","article-title":"Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates.","volume":"22","author":"Lu","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R29-2-20210131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.olq.0000223287.46097.4b","article-title":"Carrageenan\/MIV-150 (PC-815), a combination microbicide.","volume":"34","author":"Fernandez-Romero","year":"2007","journal-title":"Sex Transm Dis"},{"key":"R30-2-20210131","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-4690-5-3","article-title":"Preclinical evaluation of lime juice as a topical microbicide candidate.","volume":"5","author":"Fletcher","year":"2008","journal-title":"Retrovirology"},{"key":"R31-2-20210131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1742-4690-7-37","article-title":"Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission.","volume":"7","author":"Li","year":"2010","journal-title":"Retrovirology"},{"key":"R32-2-20210131","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMra022812","article-title":"Novel therapies based on mechanisms of HIV-1 cell entry.","volume":"348","author":"Kilby","year":"2003","journal-title":"N Engl J Med"},{"key":"R33-2-20210131","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.virol.2005.06.008","article-title":"Identification of N-phenyl-N-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.","volume":"339","author":"Zhao","year":"2005","journal-title":"Virology"},{"key":"R34-2-20210131","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0198-072","article-title":"AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.","volume":"4","author":"Donzella","year":"1998","journal-title":"Nat Med"},{"key":"R35-2-20210131","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-2-20210131","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e3181e3293a","article-title":"Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs hydroxyethyl cellulose-based universal placebo gel.","volume":"55","author":"Nel","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R37-2-20210131","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/aid.1997.13.695","article-title":"Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents.","volume":"13","author":"Hara","year":"1997","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R38-2-20210131","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1126\/science.2467383","article-title":"HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.","volume":"243","author":"Larder","year":"1989","journal-title":"Science"},{"key":"R39-2-20210131","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1128\/JVI.65.9.4887-4892.1991","article-title":"Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.","volume":"65","author":"Nunberg","year":"1991","journal-title":"J Virol"},{"key":"R40-2-20210131","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","article-title":"Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.","volume":"72","author":"Rimsky","year":"1998","journal-title":"J Virol"},{"key":"R41-2-20210131","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R42-2-20210131","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2334-6-150","article-title":"Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides.","volume":"6","author":"Neurath","year":"2006","journal-title":"BMC Infect Dis"},{"key":"R43-2-20210131","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(07)60202-5","article-title":"Microbicide drug candidates to prevent HIV infection.","volume":"369","author":"Balzarini","year":"2007","journal-title":"Lancet"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-201104150-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:28:29Z","timestamp":1618039709000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201104150-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,15]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31820a4a8d","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,15]]}}}